Aim:The aim was to assess the effect of renal angioplasty with stent on systolic, diastolic, and mean arterial blood pressure (MAP) in awake and sleep time with ambulatory blood pressure (ABP) monitoring (Holter monitoring).Materials and MethodsPatients with angiographically proven atherosclerotic renal artery stenosis (RAS) were referred to the Angiography Department of Imam Hospital for intervention during a 1-year period from June 2008 to December 2009. Primary stent placement was attempted by a single operator in 27 severe RAS cases although 1 case was omitted from the study because of technical failure. Pre- and postprocedure creatinine levels, ejection fraction (EF), history of diabetes mellitus (DM), and ABP were obtained. Twenty-six (17 men, 9 women; average age, 62.6 years; age range, 90-21 years) consecutive patients participated in the study.Results:All patients had severe hypertension resistant to multiple medications; 10 patients had impaired renal function (serum creatinine level greater than 130 µmol/L). A total of 3 (11.5%) patients had congestive heart failure, and 10 (37.7%) were diabetic. Hypertension was cured in 1 (4%) patient, had improved in 23 (88.4%) patients, and had failed to respond to treatment in 2 (7.6%). Serum creatinine decreased significantly from 1.46 ± 0.89 to 1.35 ± 0.61 mg/dL (P<0.05).Conclusion:Percutaneous transluminal angioplasty for atheromatous RAS rarely cures hypertension, but improved blood pressure control is often achieved.

‫دخول‬ ‫إعادة‬ ،)p=0.598 ‫%2.4؛‬ ‫مقابل‬ ‫األوعية‬ ‫تكوين‬ ‫وإعادة‬ ،)p=0.433 ‫%7.8)؛‬ ‫مقابل‬ 4.5%( ‫املستقرة‬ ‫غير‬ .)p=0.312 ‫%0؛‬ ‫مقابل‬ 2.2%( ‫التاجية‬ Objectives: To study the effects of low dose of empagliflozin on improving outcomes in diabetic patients with acute coronary syndrome )ACS( after percutaneous coronary intervention )PCI(. Methods: This double-blind controlled clinical trial was carried out on 93 diabetic patients )56 males and 37 females, mean age of 56.55 years( with ACS who underwent PCI at 2 university teaching hospitals in 2020, Ahvaz, Iran. The patients were randomly assigned to receive empagliflozin )10 mg once daily( or placebo at similar doses for 6 months after PCI. In addition, to standard treatments with another hypoglycemic agent. Cardiovascular outcomes )including all-cause mortality, coronary revascularization, rehospitalization due to unstable angina, hospitalization due to heart failure, Original Article cardiovascular death, non-fetal myocardial infarction, and non-fetal stroke( were evaluated during period of 6 months follow-up after the empagliflozin treatment. Results: There was no significant difference between the low dose empagliflozin and placebo groups after treatment in terms of cardiovascular mortality )2.2% versus [vs.] 4.2%; p=0.598(, rehospitalization due to unstable angina )4.5% vs. 8.7%; p=0.433(, and coronary revascularization )2.2% vs. 0%; p=0.312(. Conclusion:The results of this study showed that adding low dose empagliflozin to standard care of ACS diabetic patients after PCI was associated with no significant reduction in negative cardiovascular outcomes during 6 months.

Introduction: Nonalcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in adults, which is associated with metabolic syndrome. Aim of the research: To investigate the association of fatty liver with carotid intima-media thickness (CIMT) in patients with dyslipidaemia. Material and methods: Fifty-two patients with uncomplicated NAFLD were enrolled. Sixty-four sex-and aged-match subjects without NAFLD were considered as controls. An ultrasound was performed in the supine and left lateral positions. In all patients, CIMT was measured by high-resolution real-time B-mode ultrasonography with a 7.5-MHz linear transducer. Data, including CIMT, plasma liver function tests, and other biochemical blood measurements, were collected. Results: The mean CIMT in cases (0.66 mm) was significantly greater than the controls (0.58 mm) (p = 0.003). The mean CIMT in patients with fatty liver grade III (0.71 mm) was significantly more than the patient with fatty liver grade II (0.65 mm) (p = 0.003). Older age, hypertension, diabetes, body mass index, and smoking were associated with increased CIMT. Conclusions: In patients with NAFLD and dyslipidaemia a significant increase in the CIMT has been observed compared to the control. So, it seems that performing liver ultrasound in patients with dyslipidaemia is reasonable, and in the presence of fatty liver, assessment of carotid atherosclerotic changes is recommended, which may lead to therapeutic intervention. Considering ultrasound as a noninvasive and non-ionising radiation imaging technique, as well as its low cost and availability, may make this method an ideal candidate for a diagnosis. Streszczenie Wprowadzenie: Niealkoholowa stłuszczeniowa choroba wątroby (NAFLD) jest najczęstszym przewlekłym schorzeniem wątroby u dorosłych, które wiąże się z zespołem metabolicznym. Cel pracy: Zbadanie związku między stłuszczeniem wątroby a grubością błony środkowej i wewnętrznej tętnicy szyjnej (CIMT) u pacjentów z dyslipidemią. Materiał i metody: Do badania włączono 52 pacjentów z niepowikłaną NAFLD. Grupę kontrolną stanowiły 64 osoby różnej płci i w różnym wieku bez NAFLD. Badanie ultrasonograficzne wykonano w pozycji leżącej i bocznej lewej. U wszystkich pacjentów zmierzono CIMT podczas badania ultrasonograficznego w prezentacji B w czasie rzeczywistym o wyso kiej rozdzielczości z użyciem przetwornika liniowego 7,5 MHz. Ocenie poddano CIMT, wyniki testów czynnościowych wątroby z osocza i badania biochemiczne krwi. Wyniki: Średnia wartość CIMT u pacjentów z grupy badanej (0,66 mm) była znacznie większa niż u pacjentów z grupy kontrolnej (0,58 mm) (p = 0,003). Średnia wartość CIMT u pacjentów ze stłuszczeniem wątroby stopnia III (0,71 mm) była znacznie większa niż u pacjentów ze stłuszczeniem wątroby stopnia II (0,65 mm) (p = 0,003). Starszy wiek, nadciśnienie, cukrzyca, zwiększony wskaźnik masy ciała i palenie tytoniu były związane ze wzrostem wartości CIMT. ventitia interface) of the far wall. A carotid plaque was defined as a focal thickening ≥ 1.2 mm at the level of ...